Pacira BioSciences CFO's 150,000 options canceled
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Pacira BioSciences, Inc. CFO Shawn Cross reported three merger-related dispositions on November 17, 2026. His 9,210 common shares became a right to receive $36.50 per share, net of withholding and without interest; his RSU award covering 86,591 shares was canceled and converted to cash at the offer price, subject to tax withholding. His 150,000 options with a $16.45 exercise price were canceled for cash based on the excess, if any, of the offer price over the exercise price; his reported option position afterward was zero. Pacira became a wholly owned Viatris subsidiary.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) F3 | 150,000 | -- | -- |
| Tender Offer | Common Stock F1 | 9,210 | $36.50 | $336K |
| Disposition | Common Stock F2 | 86,591 | $36.50 | $3.16M |
Footnotes (3)
- F1. Disposed of pursuant to the Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira BioSciences, Inc. ("Issuer"), Viatris Inc. ("Viatris") and Peach Purchaser Sub Inc. ("Purchaser") (the "Merger Agreement"), pursuant to which Purchaser consummated a cash tender offer (the "Offer") to purchase all of the outstanding shares of Issuer's common stock (the "Shares") for $36.50 per Share, net of applicable withholding taxes and without interest (the "Offer Price"), after which Purchaser merged with and into Issuer with Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). On November 17, 2026, the effective time of the Merger (the "Effective Time"), each Share was converted into the right to receive the Offer Price.
- F2. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award ("RSU") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares issuable in settlement of such RSU, multiplied by (ii) the Offer Price, subject to applicable tax withholdings.
- F3. Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares ("Option") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per Share under such Option, subject to applicable tax withholdings. Each Option that was outstanding immediately prior to the Effective Time which had a per Share exercise price greater than or equal to the Offer Price was cancelled at the Effective Time with no consideration payable.
Key Figures
Key Terms
tender offer financial
restricted stock unit award financial
exercise price financial
wholly owned subsidiary financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How were Shawn Cross's PCRX options treated in the merger?
AI-generated analysis. How Rhea-AI works. Not financial advice.